In the above-named article by Burman P, Casar-Borota O, Perez-Rivas LG, and Dekkers OM (J Clin Endo Metab. 2023; doi: 10.1210/clinem/dgad098), there were typographical errors throughout the article:
The following text appeared under the “Clinical Characteristics at First Presentation (Size, Invasion, Tumor Subtype)” section: “APTs/PCs most often affect patients in their mid-40 s (median age 45; range, 3-79 years at diagnosis) (9, 11).” The text should read: “APTs/PCs most often affect patients in their mid-40 s (median age 45; range, 3-79 years at diagnosis) (6, 8).”
The following text appeared in the Figure 3 legend: “Time from diagnosis to clinically aggressive behavior in 97 patients with APT/PC. Data from (11).” The text should read: “Time from diagnosis to clinically aggressive behavior in 97 patients with APT/PC. Data from (8).”
The following text appeared under the “Peptide Receptor Radionuclide Therapy” section: “The outcome of PRRT in APTs/PCs has been reported in 19 patients, most of which were of the Pit1 lineage (6, 8, 17, 132-139) (see Fig. 6 and Table 3).” The text should read: “The outcome of PRRT in APTs/PCs has been reported in 19 patients, most of which were of the Pit1 lineage (6, 8, 17, 132-139) (see Fig. 9 and Table 3).”
In Figure 9, the columns that read, “Bevacizumab n = 19 (combined yellow), CI n = 27 (Dual yellow)” should read, “Bevacizumab n = 19 (Combined blue), ICI n = 27 (Dual blue).”
The following text appeared under the “Immune Checkpoint Inhibition” section: “Five of 18 given dual therapy and 3 of 9 given PD-1 blockade responded to the drugs (see Fig. 6).” The text should read “Five of 18 given dual therapy and 3 of 9 given PD-1 blockade responded to the drugs (see Fig. 9).”
The article has been corrected online.